Pyxis Oncology (NASDAQ:PYXS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note released on Tuesday,Benzinga reports. The brokerage currently has a $7.00 target price on the stock.

Several other research analysts have also recently issued reports on PYXS. Stephens increased their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Finally, Royal Bank Of Canada cut their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Pyxis Oncology Trading Down 4.2%

Shares of PYXS opened at $1.36 on Tuesday. The stock’s 50 day moving average is $1.52 and its two-hundred day moving average is $2.51. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The firm has a market capitalization of $84.67 million, a PE ratio of -1.05 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Tuesday, March 24th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The business had revenue of $11.04 million for the quarter. On average, sell-side analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Trading of Pyxis Oncology

A number of institutional investors have recently bought and sold shares of the company. Maia Wealth LLC acquired a new stake in Pyxis Oncology in the fourth quarter valued at $25,000. Engineers Gate Manager LP acquired a new position in shares of Pyxis Oncology during the 4th quarter worth $26,000. Fox Run Management L.L.C. purchased a new stake in shares of Pyxis Oncology in the 4th quarter worth about $26,000. Avanza Fonder AB purchased a new stake in shares of Pyxis Oncology in the 4th quarter worth about $31,000. Finally, XTX Topco Ltd acquired a new stake in Pyxis Oncology in the 2nd quarter valued at about $40,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology News Summary

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: Quarterly results beat expectations — PYXS reported a loss per share of ($0.29) vs. consensus ($0.35) and generated $11.04M of revenue, showing better-than-expected near-term performance. This beats helped validate recent operations and may support longer-term valuation recovery. Earnings Press Release
• Positive Sentiment: Clinical progress — Pyxis completed target enrollment in the Phase 1 monotherapy dose‑expansion of MICVO (micvotabart pelidotin) in 2L+ R/M HNSCC in Q1 2026. Completion of enrollment advances a near‑term clinical catalyst (data/readout) that could materially move the stock if results are positive. Business Update
• Positive Sentiment: Analyst support remains — HC Wainwright reaffirmed a “buy” rating with a $7 price target, signaling ongoing institutional conviction in the story despite the low share price. HC Wainwright Note
• Neutral Sentiment: Short-interest reporting appears anomalous — multiple March filings list 0 shares short and 0.0 days-to-cover (with NaN changes), suggesting a likely data/reporting issue rather than a meaningful shift in short positioning. Treat this as unreliable until corrected by official exchanges.
• Negative Sentiment: Price target cut by a covering analyst — Stifel Nicolaus lowered its target from $9.00 to $8.00 (but kept a “buy” rating). A lower target, even with a buy rating, can pressure sentiment and weigh on the stock in the near term. Stifel Note

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.